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a b s t r a c t
Treatment for chronic hepatitis B in Brazil are funded by the Ministry of Health and by the
state Departments of Health. Clinical protocol and therapeutic guidelines approve the use of
adefovir, entecavir, interferon-, lamivudine, and tenofovir for the treatment of chronic hep-
atitis B. The aim of this study was to establish the proﬁle of users of these drugs in the state
of Paraná. A cross-sectional studywas conductedwith patients under treatment in Paraná in
August 2011. The following data were obtained: gender, hepatitis B used drug, International
Classiﬁcation of Diseases, and regional health unit. The monthly cost of these drugs for the
public health system was also calculated. 1,093 patients registered were found, 70% male,
and 2.6% co-infected with the delta agent. Tenofovir was the drug most commonly used
(355 users). The highest prevalence was found in the regional health units of Pato Branco,
Cascavel, Foz do Iguac¸ú, Francisco Beltrão, Toledo, Londrina, and Maringá. The annual costfor the public health system in Paraná was U$1,066,867. Through this study it was possi-
ble to investigate the distribution and proﬁle of users of drugs for the treatment of chronic
in Au
treatment for patients with chronic hepatitis B, regulated
12 Elhepatitis B in Paraná
urrently, more than two billion people have been infected
y hepatitis B virus (HBV), and roughly 350 million remain
nfected. Over 500,000 people die annually due to diseases
elated to HBV infection. In addition, the frequency of hep-
titis B is still underestimated, considering that many carriers
re asymptomatic. The Ministry of Health estimates that in
razil, around 15% of the population has been exposed to the
irus, and 1% have chronic disease.1–4 There is evidence of
igher prevalence of HBV in urban populations with lower
5
© 20omplexity. However, epidemiological studies on chronic
epatitis B in Brazil are scarce and are generally performed
n speciﬁc population groups. There are high risk areas, such
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as Western and Southern Paraná, Western Santa Catarina,
Jequitinhonha, certain regions of Mato Grosso, and Western
Amazônia.2,6
The treatment of chronic hepatitis B aims to prevent or
reduce the development of liver cirrhosis and hepatocellular
carcinoma, and also aims to suppress viral replication, nor-
malize ALT levels, decrease liver damage, and obtain HBsAg
seroconversion.3,7 In Brazil, the public health system provides
sevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDto de Farmácia, Av. Pref. Lothário Meissner, 632 - Jardim Botânico,
by the clinical protocol and therapeutic guidelines for the
treatment of chronic viral hepatitis B and coinfection, pub-
lished by the Ministry of Health.4 Pharmacological options
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Table 1 – List of observed versus expected number of
registered patients with chronic hepatitis B by the
regional health units of Paraná, Brazil.
Regional health
unit
Observed
patients
Expected
patients
p Prevalence
(per 100,000
inhabitants)
01 – Paranaguá 4 28 0.000 1.39
02 – Metropolitana 298 337 0.035 8.80
03 – Ponta Grossa 14 60 0.000 2.41
04 – Irati 4 17 0.002 2.54
05 – Guarapuava 20 49 0.000 4.37
06 – União da Vitória 2 18 0.000 1.19
07 – Pato Branco 66 26 0.000 27.00
08 – Francisco Beltrão 109 35 0.000 34.78
09 – Foz do Iguac¸u 73 45 0.000 16.19
10 – Cascavel 97 53 0.000 19.33
11 – Campo Mourão 27 36 0.133 8.66
12 – Umuarama 17 27 0.056 7.26
13 – Cianorte 10 14 0.290 7.65
14 – Paranavaí 17 27 0.046 6.69
15 – Maringá 114 73 0.000 15.92
16 – Apucarana 27 35 0.156 7.99
17 – Londrina 105 88 0.068 12.41
18 – Cornélio Procópio 9 27 0.001 3.70
19 – Jacarezinho 10 30 0.000 3.68
20 – Toledo 61 35 0.000 18.85
21 – Telêmaco Borba 2 18 0.000 1.20380 braz j infect d
proposed in this protocol include conventional interferon
alpha (IFN-), pegylated interferon alpha (PEG-IFN-), and
the nucleoside/nucleotide analogs adefovir dipivoxil (ADF),
entecavir (ETV), lamivudine (LAM), and tenofovir disoproxil
fumarate (TDF).4
The Department of Health of the state of Paraná (SESA/PR),
through theCenter forDrugs in Paraná (Centro deMedicamen-
tos do Paraná – CEMEPAR), is responsible for managing the
pharmaceutical care at the state level. CEMEPAR’s activities
are structured in the pharmaceutical care cycle: scheduling,
routing the purchase, receiving, storing, and distributing to
the regional health units of Paraná.
Controlling the number of registered patients, changes in
doses prescribed by physicians, the switch and/or discontinu-
ation of drugs, the inﬂux of new patients, and the outﬂow of
other patients (cure, noncompliance, or death) are factors of
extreme importance to planning the procurement of drugs,
and to the program management. Based on this demand,
CEMEPAR, along with the informatics’ company CELEPAR,
developed in 2004 an information system called SESAFARM,
which was used as the basis for the development of the sys-
tem currently employed at national level by the Ministry of
Health Information System Component Specialized Pharma-
ceutical Services (Sistema de Medicamentos Excepcionais –
SISMEDEX). This program gives public managers the record
of the dispensed drugs in Paraná.
This study was carried out in order to proﬁle the users
of SISMEDEX, State of Paraná, fulﬁlling the provisions of the
clinic protocol for the treatment of chronic viral hepatitis B
co-infection.4 Variables such as the International Classiﬁca-
tion of Diseases (ICD), gender, regional health unit, drug used,
and co-infection with hepatitis delta virus (HDV) were evalu-
ated. The annual cost to the public health system of the drugs
used to treat these patients in Paraná was also evaluated.
This is a cross-sectional study performed by collecting data
of users registered in SISMEDEX in Paraná, duringAugust 2011.
Demographic and record dispensing data of these users were
collected by selecting the search for pathology, based on the
criteria established in the clinical protocol and therapeutic
guidelines for the treatment of chronic viral hepatitis B and
coinfection,4 considering the ICD B18.1 (without chronic hep-
atitis delta agent), and ICD B18.0 (chronic viral hepatitis B with
delta agent). For each user the following data were collected:
ICD, gender, regional health unit, and drug dispensed.
The number and percentage of patients listed were cal-
culated for each variable. Moreover, the prevalence was
calculated per 100,000 cases observed in each regional health
unit. Using the chi-squared test, the observed caseswere com-
pared with the expected values for each regional health unit,
in order to assess which regions had a higher or lower preva-
lence of chronic HBV infection than the overall prevalence of
Paraná.
The drugs used in Paraná to treat chronic hepatitis B, and
the number of users of each drug were also assessed.
To calculate the resources spent annually on the treatment
of chronic hepatitis B in Paraná, only the costs of drugs, which
were calculated according to data provided by CEMEPAR relat-
ing to remittances received from Ministry of Health in 2011,
were considered. With the cost of remittances from 2011, a
weighted average was calculated, which was multiplied by the22 – Ivaiporã 7 15 0.031 5.44
number of doses per year of the drug and the number of users
obtained in CEMEPAR.
In the population count conducted by the Brazilian Insti-
tute of Geography and Statistics in 2007, the population of
Paraná was 10,511,862, spread over 399 municipalities.8 The
number of registered users in the SISMEDEX program, receiv-
ing treatment for chronic hepatitis B during August 2011, was
1,093 (about 0.01% of the state population). Of these individ-
uals, 328 (30%) were female and 735 (70%) were male, with
signiﬁcantly (p<0.05) more male patients. Coinfection with
the delta agent (ICD 18.0) was found in 28 individuals (2.6%).
Table 1 illustrates the number of patients in each regional
health unit. Using the chi-squared test, the amount expected
for each region and the p-values for the data observed and
expected based on population distribution we calculated. The
result suggests that in most regional health units the num-
ber of patients with chronic hepatitis B was different than
expected. This difference was not seen only in regions 11, 13,
16, and 17, in which the number of patients observed was sim-
ilar to that expected (p>0.05). In addition, Table 1 presents
the prevalence of chronic hepatitis B cases per 100,000 inhab-
itants.
The overall prevalence of chronic hepatitis B in Paraná was
10.4 individuals per 100,000 inhabitants.
Regarding dispensed drugs, various regimens were
observed. Among these, ADF, ETV, IFN-, LAM and TDF
monotherapy, and combinations such as: LAM+ADF,
LAM+TDF, LAM+ETV, LAM+ IFN-, ADF+ETV, ETV+TDF,
ADF+TDF, and ETV+ IFN-.Regarding the cost of treatments, annual spendingondrugs
for chronic hepatitis B for the Brazilian Public Health System
was USD 1,066,867, and the values are shown in Table 2.
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Table 2 – Cost of each drug or combination for the public health system in Paraná, Brazil.
Drug Average cost of each dose (U$) Number of doses Annual cost (U$) Number of users Total ($)
ADF 3.35 365 1,224 28 34,280
ETV 4.98 365 1,816 218 396,031
IFN- 20.2 156 3,151 16 50,419
LAM 0.31 365 114 252 28,908
TDF 2.06 365 750 355 266,554
ADF+ETV 8.33 365 3,041 5 15,205
ADF+LAM 3.67 365 1,339 86 115,156
ADF+TDF 5.41 365 1,975 1 1,975
ETV+LAM 5.29 365 1,931 10 19,314
ETV+TDF 7.03 365 2,567 13 33,378
IFN+ETV 20.2 / 4.98 156 / 365 4,967 1 4,967
IFN+LAM 20.2 / 0.31 156 / 365 3,265 3 9,795
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Total - -
The incidence of chronic hepatitis B varies widely, depend-
ng on geographical area, and in Brazil it is more prevalent
n the states of Amazonas, Mato Grosso, Paraná, and Santa
atarina. The differences in endemicity between the various
opulation groups of the state is not well explained, but it may
e due to several factors, such as the quality and efﬁciency
f the notiﬁcations, vaccination campaigns, basic education,
anitation, effective medical care, overcrowding dwellings,
mong others.2,7,9–11Although a higher incidence of hepati-
is B is observed in males, there is no scientiﬁc evidence to
upport an increased susceptibility to viral infection in males.
his result is probably due to behavioral factors. In the current
tudy, it was found that most evaluated patients (70%) were
ales, which is in agreement with data found in literature.1,12
Of the 350 million chronic carriers of hepatitis B in the
orld, it is estimated that 18 million (approximately 5%) are
oinfected with hepatitis delta virus.1,13 In this study, 2.6%
f patients treated for chronic hepatitis B were found to be
oinfected with delta virus.
The prevalence of chronic hepatitis B in Paraná is higher in
he west and south, high risk areas for the disease.2,6 An inter-
ediate prevalence was also observed in 2003 in the cities of
ascavel, Foz do Iguac¸ú, and Francisco Beltrão.14 In this study,
he health regional units with the highest number of indi-
iduals on treatment (over 10 per 100,000 inhabitants) were
hose of Pato Branco, Cascavel, Foz do Iguacú, Francisco Bel-
rão, Toledo, Londrina, and Maringá.
In recent years, health expenditure has become a problem
specially in developing countries. The causes of increased
xpenditures are diverse and may be related to the emergence
f new technologies, often more effective and more expen-
ive. Moreover, with the emergence of new diagnostic and
herapeutic strategies, life expectancy has increased and con-
equently spending on health has increased as well. There is
constant pursuit within health systems to maximize health
ains with the use of available resources. In the current study,
he most commonly used drug in Paraná for the treatment of
hronic hepatitis B is now TDF (355 patients). However, more
esources are spent on ETV (USD 396,031/year). In this case,
t is essential to conduct cost-effectiveness studies to provide
he best allocation of healthcare resources.
This study made identiﬁed the varying prevalence rates of
hronic hepatitis B over Paraná, according to the geographic865 105 90,885
- - 1,066,867
area, suggesting that a possible difference between risk fac-
tors and protective factors may exist in each regional health
unit. Moreover, the identiﬁcation of the proﬁle of users of
drugs for the treatment of chronic hepatitis B in Paraná reg-
istered in SISMEDEX and cost of different treatments for the
public health system can assist in determining strategies for
management and prevention of morbidity and mortality.
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